Compare ROL & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROL | IQV |
|---|---|---|
| Founded | 1948 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Diversified Commercial Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5B | 28.6B |
| IPO Year | 1994 | 2013 |
| Metric | ROL | IQV |
|---|---|---|
| Price | $55.04 | $175.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | $64.55 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 13.54 | 4.67 |
| EPS | 1.09 | ★ 7.84 |
| Revenue | $2,161,220,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $10.34 | $6.77 |
| Revenue Next Year | $8.82 | $5.89 |
| P/E Ratio | $50.56 | ★ $22.55 |
| Revenue Growth | 7.23 | ★ 41.60 |
| 52 Week Low | $51.77 | $134.65 |
| 52 Week High | $66.14 | $247.05 |
| Indicator | ROL | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 49.74 | 54.48 |
| Support Level | $54.66 | $159.42 |
| Resistance Level | $58.68 | $193.26 |
| Average True Range (ATR) | 1.06 | 6.00 |
| MACD | 0.35 | 1.33 |
| Stochastic Oscillator | 69.93 | 74.66 |
Rollins is a global leader in route-based pest control services, with operations primarily in the United States and across North, Central, and South America, Europe, the Middle East, Africa, and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, a market leader in the US and Canada, with near-national coverage. It also has a portfolio of other brands, which it uses to reach customers through alternative sales channels. Residential pest and termite prevention accounts for the majority of Rollins' services, reflecting its ongoing focus on the US and Canadian markets.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its reserach and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.